TAK-475 ( DrugBank: TAK-475 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
79	家族性高コレステロール血症（ホモ接合体）	2

79. 家族性高コレステロール血症（ホモ接合体）

---

臨床試験数 : 142 /  薬物数 : 114 - (DrugBank : 29) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-003626-26-GB (EUCTR)	14/06/2006	01/11/2005	A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia	A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous familial hypercholesterolemia	Treatment of primary dyslipidemia MedDRA version: 8;Level: PT;Classification code 10058108	Product Name: TAK-475 Product Code: TAK-475	Takeda Europe R&D Centre Ltd	NULL	Not Recruiting			Female: yes Male: yes	40		United Kingdom
2	NCT00263081 (ClinicalTrials.gov)	November 2005	6/12/2005	Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia	A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia.	Hypercholesterolemia	Drug: Lapaquistat acetate and current lipid-lowering treatment;Drug: Current lipid-lowering treatment	Takeda	NULL	Terminated	8 Years	N/A	Both	44	Phase 3	United States;Canada;France;Israel;Poland;United Kingdom